propylthiouracil and Depressive-Disorder

Many conditions that require frequent medication use are common during pregnancy. The purpose of this article is to list some of the most common of these disorders and to discuss the risk to the developing fetus of the medications used most frequently to treat them. Included are drugs used for the treatment of asthma, nausea and vomiting, hyperthyroidism, pain and fever, and depression during pregnancy.

Topics: Abnormalities, Drug-Induced; Acetaminophen; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Analgesics, Non-Narcotic; Anti-Asthmatic Agents; Antidepressive Agents; Antiemetics; Antithyroid Agents; Asthma; Congenital Abnormalities; Depressive Disorder; Female; Humans; Hyperthyroidism; Leukotriene Antagonists; Maternal-Fetal Exchange; Methimazole; Morning Sickness; Ondansetron; Pregnancy; Pregnancy Complications; Propylthiouracil; Teratogens

The ability to taste 6-n-propylthiouracil (PROP) as bitter is determined genetically. The present study investigated whether this genetic ability was correlated with alcoholism and/or depression. Four groups of community college students (n = 25 each) were constituted based on the presence or absence of alcoholism and/or depression in themselves or their parents. Family history was assessed using the Family History-Research Diagnostic Criteria. Each subject was given a taste test using paper saturated with PROP. The results showed that subjects who had only alcoholism in their family were more likely to be nontasters of PROP than the control group, whereas subjects with both alcoholism and depression in their family were more likely to be so-called supertasters of PROP; that is, they found it extremely bitter. These findings suggest that PROP tasting might function as a genetic marker for two types of alcoholism.

Topics: Adolescent; Adult; Alcoholism; Depressive Disorder; Female; Genetic Markers; Hormone Antagonists; Humans; Male; Middle Aged; Propylthiouracil; Psychiatric Status Rating Scales; Taste

There are few reported convincing cases of hyperthyroid depressed patients receiving electroconvulsive therapy (ECT). We describe a depressed 66-year-old woman with catatonic depression diagnosed with new-onset hyperthyroidism due to Grave's disease. After commencing propylthiouracil, her Grave's disease was partially treated, but her depression was no better. She subsequently received a course of seven ECT with resolution of her depression and no adverse sequelae.

Topics: Aged; Antithyroid Agents; Catatonia; Depressive Disorder; Electroconvulsive Therapy; Female; Graves Disease; Humans; Propylthiouracil

Two patients are described who depended on potentiation of tricyclic antidepressant effectiveness by thyroid superfunction for remission of an episode of unipolar depression. In one case, the excess thyroid hormone was the product of hyperthyroidism; whenever the hyperthyroidism was treated, the remission induced by imipramine was negated. In the other case, triiodothyronine was exogenously administered. These case studies suggested that some patients may require larger doses than 25 microgram of triiodothyronine per day for effective antidepressant potentiation. Some endocrinological similarities between hyperthyroidism and depressive illness are discussed.

Topics: Adult; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperthyroidism; Imipramine; Middle Aged; Propylthiouracil; Triiodothyronine